Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
In the second half of 2020 medtech began a tentative – and possibly short-lived – recovery.
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
The Covid-19 pandemic has scythed vast sums from joint makers’ Q2 sales. But Medtronic’s summer earnings were better than those for its spring quarter.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.